Intellia Therapeutics Shares Plummet Once More: Here's the Reason
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 29 2025
0mins
Should l Buy NTLA?
Source: Benzinga
FDA Clinical Hold: Intellia Therapeutics announced that the FDA has placed a clinical hold on its Investigational New Drug applications for the MAGNITUDE and MAGNITUDE-2 Phase 3 trials for nexiguran ziclumeran.
Stock Impact: Following the announcement, Intellia's shares fell 16.16% in after-hours trading, dropping to $11, after previously trading near 52-week highs.
Patient Safety Measures: The company temporarily paused patient dosing and screening in the MAGNITUDE trials due to a report of serious liver-related side effects in a patient.
Next Steps: Intellia expects to receive a formal clinical hold letter from the FDA within 30 days and plans to work with the agency to resolve the hold as quickly as possible.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to rise
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 13.090
Low
4.00
Averages
16.50
High
54.00
Current: 13.090
Low
4.00
Averages
16.50
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intellia Reports Positive Phase 3 Data for Lonvo-z, Plans U.S. Launch in 2027
- Clinical Trial Success: Intellia's Phase 3 HAELO trial demonstrated that a single infusion of lonvo-z reduced HAE attacks by 87%, highlighting its potential as an innovative treatment that could significantly enhance patient quality of life.
- Regulatory Application Progress: The company has initiated a rolling Biologics License Application (BLA) for lonvo-z, with plans to complete the submission in the second half of 2026, which, if approved, will provide a unique treatment option for HAE patients and further solidify Intellia's leadership in gene editing.
- Strong Financial Position: As of March 31, 2026, Intellia reported $517.2 million in cash and cash equivalents, and with the $207 million raised from the public offering in April, the company expects to fund operations through at least 2028, ensuring the market launch of lonvo-z.
- Clinical Trials Resumed: Intellia has resumed patient screening for the MAGNITUDE and MAGNITUDE-2 trials of nex-z, with plans to complete patient enrollment in the second half of 2026, further advancing the treatment landscape for ATTR amyloidosis.
See More
Shopify and Others Tumble as Cathie Wood Buys on Dip
- Shopify Earnings Performance: Shopify reported a 34% revenue increase to $102.3 million in Q1, driven by a 35% rise in GMV, but a cautious outlook led to a 16% stock drop, indicating market concerns over its high valuation.
- Intellia's Positive Outlook: Intellia Therapeutics saw only a 4% decline, with Canaccord raising its price target from $48 to $58, reflecting confidence in positive clinical data for its CRISPR-based therapies, highlighting ongoing interest in gene editing.
- GeneDX's Disappointing Results: GeneDX's stock plummeted 49% after Q1 revenue grew only 17% to $102.3 million, falling short of the expected 30% growth, and the company lowered its 2026 revenue forecast to $475 million-$490 million, indicating significant business challenges ahead.
- Cathie Wood's Buying Strategy: Despite the negative market sentiment, Cathie Wood's Ark Invest increased its positions in Shopify, Intellia, and GeneDX during the downturn, suggesting her optimism about their long-term potential, which may attract other investors' attention.
See More
Intellia Therapeutics to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Intellia Therapeutics will participate in the Bank of America Securities Health Care Conference on May 12, 2026, with management scheduled for a fireside chat at 3:40 p.m. PT in Las Vegas, aimed at enhancing the company's visibility among investors.
- Follow-Up Conference Dates: Subsequently, Intellia will attend the RBC Capital Markets Global Healthcare Conference on May 20, 2026, with a fireside chat at 2:35 p.m. ET in New York, further expanding investor engagement.
- Multiple Engagements: Additionally, Intellia will participate in the Jefferies Global Healthcare Conference on June 3, 2026, with a fireside chat at 4:55 p.m. ET, showcasing its leadership in the gene editing field.
- Live Webcasts and Replays: All fireside chats will be webcast live on Intellia's website, with replays available for approximately 90 days post-event, ensuring that investors who cannot attend live can still access the information.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
ARK Invest Increases Holdings in Robinhood and Others Amid Stock Declines
- Increased Robinhood Holdings: ARK Invest, led by Cathie Wood, has purchased more Robinhood shares as the stock declines, indicating a long-term confidence in the company that could yield significant returns during a market rebound.
- Investment in Kratos Defense: The firm has also ramped up its investment in Kratos Defense, signaling optimism about the defense technology sector, which is expected to benefit from increased government spending and technological advancements.
- Boost in Intellia Therapeutics: ARK Invest's additional purchases of Intellia Therapeutics stock reflect a positive outlook on gene therapy and biotechnology, potentially leading to substantial returns from future medical breakthroughs.
- Sale of Bitcoin ETF: The decision to sell its Bitcoin ETF suggests ARK Invest's concerns over market volatility, indicating a strategic adjustment in its digital asset investment approach.
See More
Intellia Therapeutics Prices $180M Public Offering
- Offering Size: Intellia Therapeutics has priced an underwritten public offering of 16.74 million shares at $10.75 each, aiming for gross proceeds of approximately $180 million, which will directly enhance the company's liquidity and future R&D investments.
- Market Reaction: Following the announcement of the public offering, Intellia's stock fell 11% in premarket trading, dropping from $13.2 on Tuesday to $11.75, indicating market caution regarding the financing.
- Underwriting Arrangement: The offering is managed by Jefferies, Goldman Sachs, and Citigroup as joint book-running managers, who also received a 30-day option to purchase an additional 2.51 million shares, demonstrating flexibility in response to market demand.
- Strategic Implications: This public offering will bolster Intellia's capital base, supporting its R&D projects in gene therapy, particularly in clinical trials for hereditary angioedema, thereby further solidifying its market position.
See More
Intellia Reports Positive Phase 3 Data for Lonvo-z, Plans U.S. Launch in 2027
- Clinical Trial Success: Intellia's Phase 3 HAELO trial demonstrated that a single infusion of lonvo-z reduced HAE attacks by 87%, highlighting its potential as an innovative treatment that could significantly enhance patient quality of life.
- Regulatory Application Progress: The company has initiated a rolling Biologics License Application (BLA) for lonvo-z, with plans to complete the submission in the second half of 2026, which, if approved, will provide a unique treatment option for HAE patients and further solidify Intellia's leadership in gene editing.
- Strong Financial Position: As of March 31, 2026, Intellia reported $517.2 million in cash and cash equivalents, and with the $207 million raised from the public offering in April, the company expects to fund operations through at least 2028, ensuring the market launch of lonvo-z.
- Clinical Trials Resumed: Intellia has resumed patient screening for the MAGNITUDE and MAGNITUDE-2 trials of nex-z, with plans to complete patient enrollment in the second half of 2026, further advancing the treatment landscape for ATTR amyloidosis.
See More
Shopify and Others Tumble as Cathie Wood Buys on Dip
- Shopify Earnings Performance: Shopify reported a 34% revenue increase to $102.3 million in Q1, driven by a 35% rise in GMV, but a cautious outlook led to a 16% stock drop, indicating market concerns over its high valuation.
- Intellia's Positive Outlook: Intellia Therapeutics saw only a 4% decline, with Canaccord raising its price target from $48 to $58, reflecting confidence in positive clinical data for its CRISPR-based therapies, highlighting ongoing interest in gene editing.
- GeneDX's Disappointing Results: GeneDX's stock plummeted 49% after Q1 revenue grew only 17% to $102.3 million, falling short of the expected 30% growth, and the company lowered its 2026 revenue forecast to $475 million-$490 million, indicating significant business challenges ahead.
- Cathie Wood's Buying Strategy: Despite the negative market sentiment, Cathie Wood's Ark Invest increased its positions in Shopify, Intellia, and GeneDX during the downturn, suggesting her optimism about their long-term potential, which may attract other investors' attention.
See More
Intellia Therapeutics to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Intellia Therapeutics will participate in the Bank of America Securities Health Care Conference on May 12, 2026, with management scheduled for a fireside chat at 3:40 p.m. PT in Las Vegas, aimed at enhancing the company's visibility among investors.
- Follow-Up Conference Dates: Subsequently, Intellia will attend the RBC Capital Markets Global Healthcare Conference on May 20, 2026, with a fireside chat at 2:35 p.m. ET in New York, further expanding investor engagement.
- Multiple Engagements: Additionally, Intellia will participate in the Jefferies Global Healthcare Conference on June 3, 2026, with a fireside chat at 4:55 p.m. ET, showcasing its leadership in the gene editing field.
- Live Webcasts and Replays: All fireside chats will be webcast live on Intellia's website, with replays available for approximately 90 days post-event, ensuring that investors who cannot attend live can still access the information.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
ARK Invest Increases Holdings in Robinhood and Others Amid Stock Declines
- Increased Robinhood Holdings: ARK Invest, led by Cathie Wood, has purchased more Robinhood shares as the stock declines, indicating a long-term confidence in the company that could yield significant returns during a market rebound.
- Investment in Kratos Defense: The firm has also ramped up its investment in Kratos Defense, signaling optimism about the defense technology sector, which is expected to benefit from increased government spending and technological advancements.
- Boost in Intellia Therapeutics: ARK Invest's additional purchases of Intellia Therapeutics stock reflect a positive outlook on gene therapy and biotechnology, potentially leading to substantial returns from future medical breakthroughs.
- Sale of Bitcoin ETF: The decision to sell its Bitcoin ETF suggests ARK Invest's concerns over market volatility, indicating a strategic adjustment in its digital asset investment approach.
See More
Intellia Therapeutics Prices $180M Public Offering
- Offering Size: Intellia Therapeutics has priced an underwritten public offering of 16.74 million shares at $10.75 each, aiming for gross proceeds of approximately $180 million, which will directly enhance the company's liquidity and future R&D investments.
- Market Reaction: Following the announcement of the public offering, Intellia's stock fell 11% in premarket trading, dropping from $13.2 on Tuesday to $11.75, indicating market caution regarding the financing.
- Underwriting Arrangement: The offering is managed by Jefferies, Goldman Sachs, and Citigroup as joint book-running managers, who also received a 30-day option to purchase an additional 2.51 million shares, demonstrating flexibility in response to market demand.
- Strategic Implications: This public offering will bolster Intellia's capital base, supporting its R&D projects in gene therapy, particularly in clinical trials for hereditary angioedema, thereby further solidifying its market position.
See More
